Appili TherapeuticsAPLIF PS Ratio is 5.65 as of Jun. 29, 2026, which is 55% below its 10-year median of 12.50. The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, Appili Therapeutics ranks better than 55.24% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Appili Therapeutics's share price is $0.0113.
Appili Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Hence, Appili Therapeutics's PS Ratio for today is 5.65.
Good Sign:
Appili Therapeutics Inc stock PS Ratio (=7.5) is close to 1-year low of 7.5.
The historical rank and industry rank for Appili Therapeutics's PS Ratio or its related term are showing as below:
APLIF'
s PS Ratio Range Over the Past 10 Years
Min: 2 Med: 12.5 Max: 301.67
Current: 7.5
During the past 8 years, Appili Therapeutics's highest PS Ratio was 301.67. The lowest was 2.00. And the median was 12.50.
APLIF's PS Ratio is ranked better than 55.24% of 936
companies
in the Biotechnology industry
Industry Median: 9.155
vs APLIF: 7.50
During the past 8 years, Appili Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -20.60% per year. The lowest was -63.80% per year. And the median was -42.20% per year.
Back to Basics: PS Ratio
Appili Therapeutics (OTCPK:APLIF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Appili Therapeutics PS Ratio Related Terms
Appili Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Appili Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Appili Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Appili Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Appili Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Appili Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Appili Therapeutics's Share Price of today is $0.0113. Appili Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Appili Therapeutics (APLIF) has a PS Ratio of 5.65 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Appili Therapeutics and its competitors. This is 55% below median its historical median of 12.50. Over the past decade, Appili Therapeutics' PS Ratio has ranged from 2.00 to 301.67. According to the industry distribution chart, Appili Therapeutics ranks #419 out of 936 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Appili Therapeutics' PS Ratio too high?
Appili Therapeutics' current PS Ratio of 5.65 is 55% below median its 10-year median of 12.50. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 301.67. The Biotechnology industry median PS Ratio is 9.16. Appili Therapeutics' value of 5.65 is 38.3% below this industry median. Based on the distribution chart, Appili Therapeutics ranks #419 out of 936 companies in the Biotechnology industry, which is above the industry midpoint.
How does Appili Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Appili Therapeutics ranks #419 out of 936 companies for PS Ratio. This puts Appili Therapeutics in the upper half of its industry. The industry median PS Ratio is 9.16. Appili Therapeutics' value of 5.65 is 38.3% below this benchmark. Historically, Appili Therapeutics' own PS Ratio has ranged from 2.00 to 301.67 over the past decade. While the company's 10-year median is 12.50 vs. the industry median of 9.16, Appili Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.16, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Appili Therapeutics's current PS Ratio of 5.65 is 38.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Appili Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Appili Therapeutics's current PS Ratio is 5.65, which is 55% below median its own 10-year median of 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 43.5% below its estimated fair value. The current PS Ratio is 5.65, which is 55% below median its 10-year median of 12.50 and 38.3% below the Biotechnology industry median of 9.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current PS Ratio is 5.65 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLIF has been successfully added to your 